StreetInsider.com News Articles

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

Tue, 18 Aug 2026 15:40:00 -0400

Genentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage manufacturing roles
The milestone marks continued progress in Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S.
Powered by AI, the facility’s digital twin creates a real-time virtual model of manufacturing operations to deliver industry-leading performance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs,

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- As a cyclospora outbreak continues to spread throughout the United States,^1,2 Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with subsidiary TIB MOLBIOL, announces the availability of two

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche expands cyclospora testing portfolio to support U.S. public health response

Thu, 06 Aug 2026 08:30:00 -0400

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

Roche wins FDA clearance for vaginitis PCR diagnostic test

Fri, 24 Jul 2026 08:31:06 -0400

Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA 510(k) clearance for its cobas® BV/CV assay, a molecular diagnostic test designed to detect bacterial vaginosis (BV) and Candida vaginitis (CV) from a single vaginal swab sample.

The test uses real-time polymerase chain reaction (PCR) technology to identify DNA targets associated with BV, including Gardnerella vaginalis, Atopobium vaginae and Lactobacillus spp., as well as multiple Candida species linked to CV. Samples can be collected by a clinician or self-collected under clinician instruction using cobas® PCR Media in a healthcare setting.

The assay is intended for professional laboratory use only, based on a clinician's

Roche wins FDA clearance for vaginitis PCR diagnostic test

Fri, 24 Jul 2026 08:31:06 -0400

The assay is intended for professional laboratory use only, based on a clinician's

Roche wins FDA clearance for vaginitis PCR diagnostic test

Fri, 24 Jul 2026 08:31:06 -0400

The assay is intended for professional laboratory use only, based on a clinician's